Exosome Start-up ExoCoBio Inc. raises $26.7M in Series B Funding

ExoCoBio is the 4th largest funded exosome startup in the world
ExoCoBio is using the funding to advance its exosome pharmaceutical R&D and cosmeceutical business

SEOUL, South Korea, Sept. 12, 2018 — ExoCoBio Inc.

announced that it recently raised about $27 million in its series B

funding. Top tier Korean investors participated in this round, including

Seven Tree Equity Partners, CSQUARED Global Asset Management,

TS Investment Partners, K2 Investment, Intervest, KDB Capital, Atinum

Investment, GU Equity Partners, QUANTUM Ventures Korea, Platinum

technology Investment.

Since it was established in January 2017, ExoCoBio has raised about

$46 million accumulatively including series A round in April 2017 of $11

million.

Series B money will be used to set up GMP-compliant exosome

manufacturing facilities to produce exosome pharmaceuticals, to

attract high quality talents, and to secure additional business

opportunities for commercialization in cosmetics industry.

<BioInformant> 2018.9.26